141 related articles for article (PubMed ID: 16026246)
1. HIV vaccines: brief review and discussion of future directions.
Slobod KS; Bonsignori M; Brown SA; Zhan X; Stambas J; Hurwitz JL
Expert Rev Vaccines; 2005 Jun; 4(3):305-13. PubMed ID: 16026246
[TBL] [Abstract][Full Text] [Related]
2. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
[TBL] [Abstract][Full Text] [Related]
3. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
[TBL] [Abstract][Full Text] [Related]
4. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
5. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
6. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells.
Zhan X; Slobod KS; Surman S; Brown SA; Coleclough C; Hurwitz JL
Vaccine; 2004 Mar; 22(9-10):1206-13. PubMed ID: 15003649
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
[TBL] [Abstract][Full Text] [Related]
9. Diversity considerations in HIV-1 vaccine selection.
Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
[TBL] [Abstract][Full Text] [Related]
10. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
11. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
MacGregor RR; Boyer JD; Ciccarelli RB; Ginsberg RS; Weiner DB
J Infect Dis; 2000 Jan; 181(1):406. PubMed ID: 10608800
[No Abstract] [Full Text] [Related]
12. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
Hammonds J; Chen X; Zhang X; Lee F; Spearman P
Vaccine; 2007 Nov; 25(47):8036-48. PubMed ID: 17936444
[TBL] [Abstract][Full Text] [Related]
13. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
14. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
Nabel GJ
Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
[No Abstract] [Full Text] [Related]
15. The role of neutralizing antibodies in HIV infection.
Humbert M; Dietrich U
AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
[TBL] [Abstract][Full Text] [Related]
16. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
17. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
[TBL] [Abstract][Full Text] [Related]
18. Deceptive imprinting and immune refocusing in vaccine design.
Tobin GJ; Trujillo JD; Bushnell RV; Lin G; Chaudhuri AR; Long J; Barrera J; Pena L; Grubman MJ; Nara PL
Vaccine; 2008 Nov; 26(49):6189-99. PubMed ID: 18852005
[TBL] [Abstract][Full Text] [Related]
19. Toward an antibody-based HIV-1 vaccine.
Hoxie JA
Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
[TBL] [Abstract][Full Text] [Related]
20. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]